JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 6, 2014, Pages 2295-2300

  Etheridge, S Leah ^a   Roh, Michelle E ^a   Cosgrove, Megan E ^a   Sangkhae, Veena ^a   Fox, Norma E ^b   Chen, Junmei ^c   López, José A ^c   Kaushansky, Kenneth ^a   Hitchcock, Ian S ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; TEK PROTEIN, MOUSE;

ANIMAL; ARTICLE; BLOOD CLOTTING DISORDER; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; THROMBOCYTE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VON WILLEBRAND DISEASE;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; JANUS KINASE 2; MICE; MICE, TRANSGENIC; MYELOPROLIFERATIVE DISORDERS; RECEPTOR, TIE-2; VON WILLEBRAND DISEASES;

EID: 84893841716     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312148111     Document Type: Article

References (40)

1. Baxter EJ, et al.; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054-1061.
2. James C, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144-1148.
3. Kralovics R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779-1790.
4. Levine RL, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387-397.
5. Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285-293.
6. Carobbio A, et al. (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310-2313.
7. De Stefano V, et al.; GIMEMA CMD-Working Party (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 93(3):372-380.
8. Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 24(6):227-232.
9. Arellano-Rodrigo E, et al. (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91(2):169-175.
10. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110(1):116-124.
11. Landolfi R, Rocca B, Patrono C (1995) Bleeding and thrombosis in myeloproliferative disorders: Mechanisms and treatment. Crit Rev Oncol Hematol 20(3):203-222.
12. Schafer AI (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood 64(1):1-12.
13. Carobbio A, et al. (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112(8):3135-3137.
14. Cortelazzo S, et al. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132-1136.
15. Landolfi R, Cipriani MC, Novarese L (2006) Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 19(3):617-633.
16. Falanga A, Marchetti M, Barbui T, Smith CW (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils. Semin Hematol 42(4):239-247.
17. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33(5):523-530.
18. Afshar-Kharghan V, Thiagarajan P (2006) Leukocyte adhesion and thrombosis. Curr Opin Hematol 13(1):34-39.
19. Falanga A, et al. (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96(13): 4261-4266.
20. Sozer S, et al. (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113(21):5246-5249.
21. Teofili L, et al. (2011) Endothelial progenitor cells are clonal and exhibit the JAK2 (V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 117(9):2700-2707.
22. Tiedt R, et al. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111(8):3931-3940.
23. Hitchcock IS, et al. (2008) Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: Studies using a megakaryocyte lineage specific FAK knockout. Blood 111(2):596-604.
24. Kisanuki YY, et al. (2001) Tie2-Cre transgenic mice: A new model for endothelial celllineage analysis in vivo. Dev Biol 230(2):230-242.
25. Tang Y, Harrington A, Yang X, Friesel RE, Liaw L (2010) The contribution of the Tie2+ lineage to primitive and definitive hematopoietic cells. Genesis 48(9):563-567.
26. Tiedt R, Schomber T, Hao-Shen H, Skoda RC (2007) Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 109(4):1503-1506.
27. Weskamp G, et al. (2010) Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 106(5):932-940.
28. Zhou L, et al. (2009) Tie2cre-induced inactivation of the miRNA-processing enzyme Dicer disrupts invariant NKT cell development. Proc Natl Acad Sci USA 106(25): 10266-10271.
29. Michiels JJ, et al. (2006) The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32(6):589-604.
30. Denis C, et al. (1998) A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 95(16):9524-9529.
31. Matsushita K, et al. (2003) Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115(2):139-150.
32. Qian Z, et al. (2001) Inducible nitric oxide synthase inhibition of weibel-palade body release in cardiac transplant rejection. Circulation 104(19):2369-2375.
33. Dimmeler S, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 399(6736):601-605.
34. Rosti V, et al.; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121(2):360-368.
35. Karakantza M, et al. (2004) Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 79(3): 253-259.
36. Aird WC (2012) Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2(1): a006429.
37. Laszik Z, Mitro A, Taylor FB, Jr., Ferrell G, Esmon CT (1997) Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway. Circulation 96(10):3633-3640.
38. Levin EG, Banka CL, Parry GC (2000) Progressive and transient expression of tissue plasminogen activator during fetal development. Arterioscler Thromb Vasc Biol 20(6): 1668-1674.
39. Osterud B, Bajaj MS, Bajaj SP (1995) Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 73(5):873-875.
40. Constien R, et al. (2001) Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30(1):36-44.